Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) on Friday, April 11, announced that it has received final approval from the United ...

Ahmedabad: Pharma major, Zydus Lifesciences Limited has received final approval from the United States Food and Drug ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ...

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to manufacture ...

Zydus Lifesciences has secured final approval from the US Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) tablets in four strengths - 6 mg, 18 mg, 30 mg, and 36 mg.

The drugmaker has received the USFDA's final approval to manufacture a particular corticosteroid called Deflazacort to treat Duchenne muscular dystrophy.

Zydus Lifesciences: The company will acquire 85.6% equity shares of Amplitude Surgical SA, France, at a price of Euro 6.25 ...

Jaythari is indicated for the treatment of DMD, a rare and genetic disease that results in ongoing muscle weakness and degeneration.